Clinical trials: Cardiovascular Condition
Lower Limb; Sprain (Strain), Lower Limb Fracture
Implementation of an App-based Walking Aid Skills Training Program
Walking aids (WA), such as crutches, canes, and walkers allow individuals to move independently after lower body impairment. Improper WA use may lead to upper body discomfort, pain, or injury.
- Conditions
- Lower Limb; Sprain (Strain), Lower Limb Fracture, Stroke, Multiple Sclerosis
- Trial name
- NCT05347875
- Testing
- Walking aid skills app, Breathing skills app
- Where
- 2 sites in Canada
- Volunteers
- 52 people
- Sponsor
- University of Calgary
Hemodynamics Instability
Non-invasive Goal-directed thErapy oN cIrcUlatory Shock
Circulatory shock occurs when the oxygen supply to the tissues decreases, leading to cellular damage and affecting about one-third of patients admitted to Intensive Care Units (ICUs).
- Trial name
- GENIUS (NCT05336357)
- Testing
- Goal-Directed Therapy
- Where
- Brazil
- Volunteers
- 380 people
- Sponsor
- University of Sao Paulo
Diabetic Retinopathy
Pivotal Trial to Assess the Clinical Performance of Ophthal-360 for the Detection of Diabetic Retinopathy
Multicenter, prospective, study to assess the performance of the Ophthal-360 platform in the diagnosis of more-than-mild Diabetic Retinopathy (mtmDR) in diabetic patients with no previous diagnosis of DR.
- Trial name
- NCT05806957
- Testing
- Fundus Photography
- Volunteers
- 500 people
- Sponsor
- Ophthalytics, Inc.
Thoracoabdominal Aortic Aneurysm
Investigation of the Cerebrospinal Fluid and Further Tissue Samples for Biomarker Indicating Spinal Ischemia and Organ Failure in Patients With Thoracoabdominal Aortic Aneurysm
Patients with a thoracoabdominal aortic aneurysm in need of an endovascular or open operative restructuring will be asked to participate in this study.
- Trial name
- TAAA (NCT03093857)
- Testing
- Determination of biomarker
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- RWTH Aachen University
Cardiovascular Disease
Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
The aim of this study was to estimate the number of United States (US) adults with and without prior atherosclerotic cardiovascular disease (ASCVD) and diabetes who may be eligible for inclisiran based on US National Health and…
- Trial name
- NCT07214857
- Where
- United States
- Volunteers
- 1,385 people
- Sponsor
- Novartis Pharmaceuticals
Hereditary Angioedema, Angioneurotic Edema
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
Hereditary angioedema ("HAE") is a genetic disorder characterized by sudden recurrent attacks of local swelling (angioedema). These attacks are often painful and disabling, and, in some cases, life-threatening.
- Conditions
- Hereditary Angioedema, Angioneurotic Edema, Genetic Disorders
- Trial name
- NCT00262301
- Testing
- recombinant human C1 inhibitor
- Where
- 2 sites in Netherlands, Romania
- Volunteers
- 75 people
- Sponsor
- Pharming Technologies B.V.
Hypoxic-Ischemic Encephalopathy, Cardiac Arrest
Propofol-induced EEG Changes in Hypoxic Brain Injury
PROPEA3 is a prospective observational study investigating the recovery of propofol-induced EEG slow-wave activity and its association with neurological outcome after cardiac arrest.
- Trial name
- PROPEA3 (NCT03485781)
- Where
- 2 sites in Finland
- Volunteers
- 102 people
- Sponsor
- University of Oulu
Spinal Cord Injury, Orthostatic Hypotension
ARC Therapy to Restore Hemodynamic Stability and Trunk Control in People With Spinal Cord Injury
The goal of this interventional study is to evaluate the safety and preliminary effectiveness of the ARC-IM Therapy to improve hemodynamic management in people with sub-acute or chronic spinal cord injury.
- Trial name
- HemON-NL (NCT05941819)
- Testing
- ARC-IM Thoracic System implantation
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- ONWARD Medical, Inc.
Heart Failure
Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients
This phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa®).
- Trial name
- TROJAN-C (NCT03383419)
- Testing
- Epclusa
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Baylor Research Institute
Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with feladilimab (GSK3359609), and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore…
- Trial name
- NCT07217119
- Testing
- Belantamab mafodotin, Feladilimab
- Where
- 11 sites in United States, Australia and 6 more
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Cardiovascular Disease
The Fibrin Pad Cardiovascular Study
This is a three-arm, randomized multicenter study evaluating the safety and effectiveness of EVARREST™ Fibrin Sealant Patch in controlling mild to moderate vascular anastomosis suture line bleeding in cardiovascular surgery.
- Trial name
- NCT01681030
- Testing
- EVARREST™, Topical hemostat, Standard of Care
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- Ethicon, Inc.
Coronary Artery Disease
COmparison and Modification in Neointimal Pattern Assessed by Optical Coherence Tomography With High Versus Moderate Efficacy Statin Treatment After Drug Eluting Stent Implantation: COMPASS Trial
This study is a prospective randomized trial to evaluate and compare the quantitative and qualitative characteristics of neointimal formation between high and low efficacy statin treatment after drug eluting stent (DES)…
- Trial name
- NCT02155530
- Testing
- Atorvastatin 40mg, pravastatin 20 mg
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Yonsei University
Venous Leg Ulcer, Diabetic Foot Ulcer
A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers
This study will be a multicenter, prospective, open label, one-arm study intended to assess the clinical performance and safety of EX-02 in debridement of lower leg ulcers: Venous Leg Ulcers (VLU) and Diabetic Foot Ulcer (DFU).
- Trial name
- NCT04817228
- Testing
- EscharEx (EX-02 formulation)
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- MediWound Ltd
Atrial Fibrillation, Stroke
AI-Assisted Workflow for Occult Atrial Fibrillation Detection After Ischemic Stroke: A Prospective Randomized Trial
We hypothesize that an AI-guided AF risk stratification approach, particularly when combined with intensified rhythm monitoring using wearable devices and extended ECG patches, will significantly increase AF detection rates…
- Conditions
- Atrial Fibrillation, Stroke, Artificial Intelligence
- Trial name
- AI-AFIS (NCT07540065)
- Testing
- Active Follow-up Group, Standard Follow-up Group
- Where
- Taiwan
- Volunteers
- 400 people
- Sponsor
- National Taiwan University Hospital
Hereditary Cystatin C Amyloid Angiopathy (HCCAA), Hemorrhage Brain
Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)
The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with Hereditary Cystatin C Amyloid Angiopathy (HCCAA).
- Conditions
- Hereditary Cystatin C Amyloid Angiopathy (HCCAA), Hemorrhage Brain, Hemorrhage Cerebral
- Trial name
- HCCAA (NCT07716865)
- Testing
- NACA
- Where
- Iceland
- Volunteers
- 15 people
- Sponsor
- Arctic Therapeutics
Atrial Fibrillation
Laser Ablation Study for trEatment of atRial Fibrillation (LASER)
This protocol aims at assessing the efficacy of performing catheter ablation for atrial fibrillation (AF) with laser catheters versus performing it with radiofrequency (RF) catheters.
- Trial name
- LASER (NCT02504567)
- Testing
- Laser ablation, RF ablation
- Where
- Spain
- Volunteers
- 64 people
- Sponsor
- Hospital Clinic of Barcelona
Hypertension
A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure
After a wash-out (1 to 2 weeks), and 2 to 4 week single-blind placebo run-in period, eligible patients will be randomized to receive lisinopril 10 mg, aliskiren 75 mg, 150 mg or 300 mg for a period of 8 weeks
- Trial name
- NCT00219167
- Testing
- aliskiren
- Where
- Switzerland
- Volunteers
- 355 people
- Sponsor
- Novartis
Coronary Artery Disease (CAD)
Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)
The primary objective is to evaluate the safety and feasibility of using M118 as an anticoagulant in the target population of subjects with stable coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI).
- Trial name
- EMINENCE (NCT00543400)
- Testing
- M118, Unfractionated Heparin
- Where
- 44 sites in United States, Canada
- Volunteers
- 503 people
- Sponsor
- Momenta Pharmaceuticals, Inc.
Preeclampsia
Marinobufagenin as a Target for DIGIBIND in Preeclampsia
Background: Preeclampsia is a combination of high blood pressure and other potentially life-threatening symptoms. Preeclampsia occurs in up to 10% of pregnancies and is a main cause of maternal and fetal death worldwide.
- Trial name
- NCT01328600
- Where
- 3 sites in Russia
- Volunteers
- 144 people
- Sponsor
- National Institute on Aging (NIA)
Stroke, Inflammation
Combinating Fingolimod With Alteplase Bridging With Mechanical Thrombectomy in Acute Ischemic Stroke
Proof-of concept clinical trials have indicated that the sphingosine-1-phosphate receptor modulator fingolimod may be efficacious in attenuating brain inflammation and improving clinical outcomes in patients with AIS as a single…
- Trial name
- FAMTAIS (NCT02956200)
- Testing
- Fingolimod
- Where
- China
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.